Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Sanofi
Deal Size : $1,055.0 million
Deal Type : Collaboration
Fulcrum and Sanofi Collaborate On Losmapimod for Muscular Dystrophy
Details : Sanofi receives exclusive rights to commercialize FTX-1821 (losmapimod), an oral small molecule being investigated for facioscapulohumeral muscular dystrophy (FSHD), in all territories outside the US.
Brand Name : FTX-1821
Molecule Type : Small molecule
Upfront Cash : $80.0 million
May 13, 2024
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Sanofi
Deal Size : $1,055.0 million
Deal Type : Collaboration
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FTX-1821 (losmapimod) is a small molecule, which is act as selective p38alpha/beta mitogen activated protein kinase (MAPK) inhibitor, which is investigated for the treatment of facioscapulohumeral muscular dystrophy.
Brand Name : FTX-1821
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 07, 2023
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : FSHD Society
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims for the development of FTX-1821 (losmapimod), an investigational small molecule inhibitor of p38α/β Mitogen Activated Protein Kinase (MAPK), for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Brand Name : FTX-1821
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 20, 2023
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : FSHD Society
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $125.0 million
Deal Type : Public Offering
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Details : Fulcrum Therapeutics intends to use the net proceeds for the development of FTX-1821 (losmapimod), a small molecule, for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Brand Name : FTX-1821
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 17, 2023
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $125.0 million
Deal Type : Public Offering
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Results reported from the ReDUX4 trial demonstrated slowed disease progression and improved function, including positive impacts on upper extremity strength, supporting Losmapimod’s (FTX-1821) potential to be a transformative therapy for the treatment ...
Brand Name : FTX-1821
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2022
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Losmapimod is an oral small molecule that selectively inhibit p38α/β mitogen activated protein kinase (MAPK) has the potential to be the first therapy to treat FSHD, the second most common form of muscular dystrophy.
Brand Name : FTX-1821
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 05, 2022
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Losmapimod is an investigational, selective p38α/β mitogen activated protein kinase (MAPK) inhibitor, that demonstrates potential to slow or stop disease progression in facioscapulohumeral muscular dystrophy from its clinical data.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 01, 2022
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Results from Phase 2b clinical trial demonstrated that losmapimod, an investigational, selective p38α/β mitogen-activated protein kinase inhibitor, slowed disease progression and improved function in people with FSHD. Based on these data company initia...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 03, 2022
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Losmapimod showed statistically significant* and clinically relevant benefit across multiple structural, functional and patient reported endpoints. Losmapimod was well tolerated with no treatment related discontinuations or treatment related serious adve...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 24, 2021
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Fulcrum will present four posters on its integrated approach to the evaluation of FSHD patients, highlighting the progress made in the development of imaging and molecular biomarkers in FSHD and the design of clinical trials of losmapimod in FSHD patient...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2020
Lead Product(s) : Losmapimod
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?